跳至主要内容
临床试验/NCT02718521
NCT02718521Unknown不适用

Chinese People's Liberation Army General Hospital

Chinese PLA General Hospital1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2016年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
400
试验地点
1
主要终点
Contrast induced nephropathy postoperation

研究概览

简要总结

Patients at moderate and high risk for contrast induced nephropathy (CIN) should receive sufficient hydration before application of contrast to prevent CIN, but hydration could obviously increase the preload for congestive heart failure (CHF) patients. Isosorbide Dinitrate could reduce cardiac preload and afterload by expanding vein and artery.so adequate hydration therapy combined with intravenous infusion of isosorbide dinitrate could better prevent contrast-induced nephropathy theoretically.This prospective, randomized, double-blind, comparative clinical trial randomly selected 264 patients with estimated glomerular filtration rate, (eGFR) <60 ml/min per 1.73 m2 and CHF undergoing coronary angiography to receive either the convention hydration (n=200) or the hydration therapy combined with intravenous infusion of isosorbide dinitrate(n=200).

详细描述

Investigators enroll 400 patients from February 2016 to February 2017, the principal inclusion criterion included CHF: left ventricular eject fraction (LVEF) <= 50%; moderate to severe chronic kidney disease(CKD) was diagnosed as an eGFR 15 to 59 mL/min per 1.73 m2, calculated via the abbreviated Modification of Diet in Renal Disease (MDRD) study equation from SCr obtained within 72 hours of enrollment, patients were scheduled to undergo diagnostic cardiac angiography or percutaneous coronary interventions. We randomly assigned eligible patients in a 1:1 ratio to either the hydration therapy combined with intravenous infusion of isosorbide dinitrate or a standard hydration administration protocol. hydration therapy combined with intravenous infusion of isosorbide dinitrate refer to give intravenous infusion of isosorbide dinitrate on the basis of fully hydration to reduce cardiac preload.afterload and increase the the tolerance degreen of hydration in chronic heart failure patients. both study groups received intravenous fluids for the same hydration dose. All study participants received intra-arterial Visipaque(320 mg I/ml; GE Healthcare) iso-osmolar contrast medium.

Primary end point of the study was the incidence of CIN: The median peak increase in serum creatinine concentration between day 0 (when contrast was administered) and day 7. Definition of CIN was an absolute increase in serum creatinine (SCr) >0.5 mg/dl or a relative increase >25% compared to baseline SCr. Definition of non-Q-wave myocardial infarction was a creatine kinase-myocardial band enzyme elevation 3 times the upper normal value without new Q waves on the electrocardiogram. Definition of Q-wave myocardial infarction was presence of new pathologic Q waves on an electrocardiogram in conjunction with an elevation in creatine kinase greater than 3 times the normal value. All adverse clinical events as well as study end points were monitored and adjudicated by the independent event committee. Each patient was contacted in every week after administration of the contrast, investigated if dialysis or main cardiovascular events (myocardial infarction,acute heart failure and death), and record any adverse events.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • congestive heart failure: objective evidences for decreased left ventricular eject fraction (LVEF) <= 50%;
  • moderate to severe chronic kidney disease was defined as an eGFR 15 to 59 mL/min per 1.73 m2, calculated via the abbreviated Modification of Diet in Renal Disease (MDRD) study equation from SCr obtained within 72 hours of enrollment;
  • patients were scheduled to undergo diagnostic cardiac angiography or percutaneous coronary interventions.

排除标准

  • hemodialysis-dependent patients;
  • complicated with severe short-term progressive disease;
  • Patients < 18 years;
  • emergency cardiac catheterisation (eg, primary percutaneous coronary intervention for ST-segment elevation myocardial infarction);
  • exposure to radiographic contrast media within the previous 7 days;
  • acute decompensated heart failure.

研究组 & 干预措施

Hydration Therapy Combined With Isosorbide Dinitrate

Experimental

Intravenous Infusion of Isosorbide Dinitrate 2mg/h combined with normal saline 1 ml/kg·h 6 hours before angiography and 12 hours after angiography

干预措施: Hydration Combined With Intravenous Infusion of Isosorbide Dinitrate (Procedure)

Hydration Therapy Combined With Isosorbide Dinitrate

Experimental

Intravenous Infusion of Isosorbide Dinitrate 2mg/h combined with normal saline 1 ml/kg·h 6 hours before angiography and 12 hours after angiography

干预措施: Visipaque (Drug)

Hydration Therapy Combined With Isosorbide Dinitrate

Experimental

Intravenous Infusion of Isosorbide Dinitrate 2mg/h combined with normal saline 1 ml/kg·h 6 hours before angiography and 12 hours after angiography

干预措施: 0.9% sodium chloride fluid administration (Drug)

Hydration Therapy Combined With Isosorbide Dinitrate

Experimental

Intravenous Infusion of Isosorbide Dinitrate 2mg/h combined with normal saline 1 ml/kg·h 6 hours before angiography and 12 hours after angiography

干预措施: isosorbide dinitrate (Drug)

Conventional hydration group

Active Comparator

normal saline 0.5 ml/kg·h 6 hours before angiography and 12 hours after angiography

干预措施: Hydration Combined With Intravenous Infusion of Isosorbide Dinitrate (Procedure)

Conventional hydration group

Active Comparator

normal saline 0.5 ml/kg·h 6 hours before angiography and 12 hours after angiography

干预措施: Visipaque (Drug)

Conventional hydration group

Active Comparator

normal saline 0.5 ml/kg·h 6 hours before angiography and 12 hours after angiography

干预措施: 0.9% sodium chloride fluid administration (Drug)

结局指标

主要结局

Contrast induced nephropathy postoperation

时间窗: 7 days

a peak serum creatinine increase of either 0.5 mg/dl or 25% from day 0 through day 7

次要结局

  • Composite measure of dialysis or main cardiovascular events(90 days)

研究者

发起方
Chinese PLA General Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Qian geng

Associate attending doctor

Chinese PLA General Hospital

研究点 (1)

Loading locations...

相似试验